We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

81 hedge funds and large institutions have $386M invested in Oruka Therapeutics in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 14

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

18% more capital invested

Capital invested by funds: $326M → $386M (+$59.9M)

14% more funds holding

Funds holding: 71 → 81 (+10)

7.08% more ownership

Funds ownership: 84.87% → 91.96% (+7.1%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
25
Increased
27
Reduced
14
Closed
15
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.9M
2
Mercer Global Advisors
Mercer Global Advisors
Colorado
+$8.88M
3
DTC
Deep Track Capital
Connecticut
+$4.94M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.7M
5
Franklin Resources
Franklin Resources
California
+$3.05M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$3.97M
2
JFG
Jefferies Financial Group
New York
-$3.54M
3
Morgan Stanley
Morgan Stanley
New York
-$3.33M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.29M
5
Goldman Sachs
Goldman Sachs
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
76
Parallel Advisors
California
$224 – – –
National Bank of Canada
77
National Bank of Canada
Quebec, Canada
$89 – – –
AF
78
Allworth Financial
California
$57 +$52 +5 New
SS
79
SBI Securities
Japan
$22 +$21 +2 New
CIAM
80
Caitong International Asset Management
Hong Kong
$11 +$10 +1 New
Osaic Holdings
81
Osaic Holdings
Arizona
$11 +$10 +1 New
RG
82
Redmile Group
California
– -$3.97M -386,963 Closed
Wellington Management Group
83
Wellington Management Group
Massachusetts
– -$898K -87,501 Closed
Qube Research & Technologies (QRT)
84
Qube Research & Technologies (QRT)
United Kingdom
– -$534K -52,026 Closed
HF
85
HRT Financial
New York
– -$477K -46,511 Closed
OAC
86
OMERS Administration Corp
Ontario, Canada
– -$461K -44,900 Closed
WAM
87
Weiss Asset Management
Massachusetts
– -$410K -40,000 Closed
ECM
88
ExodusPoint Capital Management
New York
– -$368K -35,912 Closed
Man Group
89
Man Group
United Kingdom
– -$301K -29,365 Closed
OQS
90
Occudo Quantitative Strategies
Florida
– -$310K -24,804 Closed
Squarepoint
91
Squarepoint
New York
– -$226K -22,022 Closed
AI
92
Allostery Investments
Connecticut
– -$205K -20,000 Closed
CGIM
93
Cannon Global Investment Management
Florida
– -$195K -19,000 Closed
AGP
94
Artia Global Partners
Florida
– -$75.7K -7,380 Closed
Group One Trading
95
Group One Trading
Illinois
– -$22K -2,108 Closed
CCM
96
Coldstream Capital Management
Washington
– -$1.85K -180 Closed
1 2 3
4

ORKA Hedge Fund Activity: Q2 2025 in Review

81 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2025, worth a combined $386M — up 18% from $326M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ORKA positions and 15 closed out — a net gain of 10 holders — while 27 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was Redmile Group, exiting entirely with an estimated $3.97M sold.

  • 81 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2025, up from 71 in Q1 2025.
  • Funds reported $386M of Oruka Therapeutics stock for Q2 2025, up 18% quarter-over-quarter.
  • 25 funds opened new Oruka Therapeutics positions in Q2 2025 and 15 closed out, a net change of +10 holders.
  • The largest Oruka Therapeutics buyer in Q2 2025 was BlackRock, an estimated $12.9M added.
  • The largest Oruka Therapeutics seller in Q2 2025 was Redmile Group, an estimated $3.97M sold.

Based on aggregated 13F filings for Q2 2025.